HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease.

Abstract
Significance: The metabolic disorder, diabetes mellitus, results in microvascular complications, including diabetic kidney disease (DKD), which is partly believe to involve disrupted energy generation in the kidney, leading to injury that is characterized by inflammation and fibrosis. An increasing body of evidence indicates that the innate immune complement system is involved in the pathogenesis of DKD; however, the precise mechanisms remain unclear. Recent Advances: Complement, traditionally thought of as the prime line of defense against microbial intrusion, has recently been recognized to regulate immunometabolism. Studies have shown that the complement activation products, Complement C5a and C3a, which are potent pro-inflammatory mediators, can mediate an array of metabolic responses in the kidney in the diabetic setting, including altered fuel utilization, disrupted mitochondrial respiratory function, and reactive oxygen species generation. In diabetes, the lectin pathway is activated via autoreactivity toward altered self-surfaces known as danger-associated molecular patterns, or via sensing altered carbohydrate and acetylation signatures. In addition, endogenous complement inhibitors can be glycated, whereas diet-derived glycated proteins can themselves promote complement activation, worsening DKD, and lending support for environmental influences as an additional avenue for propagating complement-induced inflammation and kidney injury. Critical Issues: Recent evidence indicates that conventional renoprotective agents used in DKD do not target the complement, leaving this web of inflammatory stimuli intact. Future Directions: Future studies should focus on the development of novel pharmacological agents that target the complement pathway to alleviate inflammation, oxidative stress, and kidney fibrosis, thereby reducing the burden of microvascular diseases in diabetes. Antioxid. Redox Signal. 37, 781-801.
AuthorsSih Min Tan, Matthew Snelson, Jakob A Østergaard, Melinda T Coughlan
JournalAntioxidants & redox signaling (Antioxid Redox Signal) Vol. 37 Issue 10-12 Pg. 781-801 (Oct 2022) ISSN: 1557-7716 [Electronic] United States
PMID34806406 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
Chemical References
  • Carbohydrates
  • Complement Inactivating Agents
  • Inflammation Mediators
  • Lectins
  • Reactive Oxygen Species
  • Complement C5a
Topics
  • Carbohydrates
  • Complement C5a (metabolism)
  • Complement Inactivating Agents (metabolism)
  • Diabetes Mellitus (metabolism)
  • Diabetic Nephropathies (etiology, metabolism)
  • Fibrosis
  • Humans
  • Inflammation (metabolism)
  • Inflammation Mediators (metabolism)
  • Kidney (metabolism)
  • Lectins (metabolism)
  • Reactive Oxygen Species (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: